
Gastroenterologist

No OPD information available
Colitis
Viral Gastroenteritis
Crohn's Disease
Hemorrhagic Proctocolitis
Ulcerative Colitis
Cirrhosis
Colonoscopy
Congenital Fiber-Type Disproportion
Diverticular Disease
Endoscopy
Lymphoid Hyperplasia
Mouth Sores
Mouth Ulcers
Muscle Atrophy
Necrosis
Non-Alcoholic Fatty Liver Disease
Tubular Aggregate Myopathy
X-Linked Lymphoproliferative Disease
X-Linked Myotubular Myopathy
Gregory T. Moore is a male healthcare provider who helps patients with various digestive and liver issues. He specializes in conditions like colitis, Crohn's disease, ulcerative colitis, and liver diseases. He also performs procedures like colonoscopies and endoscopies. Some of the other conditions he treats include muscle atrophy, mouth sores, and fatty liver disease.
Gregory T. Moore is known for his special skills in diagnosing and treating gastrointestinal problems. He is good at communicating with his patients, making them feel comfortable and cared for. Patients trust him because he listens to their concerns and explains things in a way they can understand.
To stay updated with the latest medical knowledge, Gregory T. Moore regularly reads research papers and attends conferences. This helps him provide the best care for his patients. He also collaborates with other medical professionals to discuss cases and learn from each other.
Gregory T. Moore's work has had a positive impact on many patients' lives. His research on inflammatory bowel disease during pregnancy has helped improve outcomes for pregnant women with these conditions. He is also involved in clinical trials to find new treatments for ulcerative colitis in children.
One of his notable publications talks about the risks associated with inflammatory bowel disease during pregnancy. This research helps doctors better care for pregnant women with these conditions. Gregory T. Moore's dedication to research and patient care makes him a respected healthcare provider in his field.
Enrollment Status: Active not recruiting
Published: September 20, 2024
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
